Converge Bio
Generative AI Platform for Biological Engineering
Company Overview
Snapshot
Founded in May 2024 by Oded Kalev, Converge Bio operates with 11–50 employees and has raised $33M across three funding rounds from four investors. In January 2026, the company secured an A Round of funding, led by Bessemer Venture Partners.
Business overview
Converge Bio is revolutionizing biological R&D through its Generative AI platform, which focuses on designing DNA, RNA, and protein sequences. The company's core product, ConvergeAB, is designed to accelerate drug discovery and development. Converge Bio serves the health tech and life sciences sectors, with a particular emphasis on pharmaceuticals and biotechnology.
Strategic signal
In June 2026, Converge Bio secured a grant to expand its AI gene discovery capabilities beyond pharmaceuticals into growing climate-resilient crops. This strategic move signals the company's ambition to diversify its application areas, leveraging its core generative AI technology to address broader challenges in biotechnology and agricultural innovation, potentially opening new market opportunities and demonstrating the versatility of its platform.
Log in to access full profile ›Company Intelligence Q&A
- What is Converge Bio's primary focus?
- Converge Bio's primary focus is to revolutionize biological R&D by creating a Generative AI platform for DNA, RNA, and protein sequences, aiming to accelerate drug discovery and development.
- When was Converge Bio founded?
- Converge Bio was founded in May 2024.
- What was a significant recent development for Converge Bio in the climate sector?
- In June 2026, Converge Bio secured a grant from the Bill & Melinda Gates Foundation to expand its fast-track AI gene discovery capabilities from pharmaceuticals to growing climate-resilient crops.
- Which investors participated in Converge Bio's A Round funding?
- In January 2026, Converge Bio secured an A Round of funding, with.
- What product did Converge Bio use to improve a cancer treatment?
- In May 2026, Converge Bio utilized its product, ConvergeAB, to improve a popular cancer treatment with a single prompt.